Understanding Bruton Tyrosine Kinase (BTK) Pathway Inhibition in B-cell Malignancies
This slide deck provides information on covalent and reversible (non-covalent) BTK inhibition in the treatment of B-cell malignancies, and a growing unmet need of resistance to covalent BTK inhibition.
Date of Last Review: May 16, 2022
Are you satisfied with this content?